MCID: MYL075
MIFTS: 49

Myelodysplastic/myeloproliferative Neoplasm

Categories: Blood diseases, Cancer diseases, Rare diseases

Aliases & Classifications for Myelodysplastic/myeloproliferative Neoplasm

MalaCards integrated aliases for Myelodysplastic/myeloproliferative Neoplasm:

Name: Myelodysplastic/myeloproliferative Neoplasm 12 52 15 37 17
Myelodysplastic/myeloproliferative Disease 52 58
Myeloproliferative/myelodysplastic Syndromes 12
Myelodysplastic-Myeloproliferative Diseases 43
Myelodysplastic Myeloproliferative Disease 12
Myelodysplastic Myeloproliferative Cancer 12

Classifications:

Orphanet: 58  
Rare haematological diseases


External Ids:

Disease Ontology 12 DOID:4972
MeSH 43 D054437
NCIt 49 C27262
ICD10 32 C94.6
MESH via Orphanet 44 D054437
UMLS via Orphanet 72 C1301355
Orphanet 58 ORPHA98275
UMLS 71 C1301355

Summaries for Myelodysplastic/myeloproliferative Neoplasm

NIH Rare Diseases : 52 Myelodysplastic/myeloproliferative diseases are a group of diseases of the blood and bone marrow in which the bone marrow makes too many white blood cells . These disease have features of both myelodysplastic syndromes and myeloproliferative disorders . In myelodysplastic diseases, the blood stem cells do not mature into healthy red blood cells , white blood cells , or platelets and as a result, there are fewer of these healthy cells. In myeloproliferative diseases, a greater than normal number of blood stem cells develop into one or more types of blood cells and the total number of blood cells slowly increases. The 3 main types of myelodysplastic/myeloproliferative diseases include chronic myelomonocytic leukemia (CMML); juvenile myelomonocytic leukemia (JMML); and atypical chronic myelogenous leukemia (aCML). When a myelodysplastic/myeloproliferative disease does not match any of these types, it is called myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-UC). Symptoms of CMML and JMML may include fever, feeling tired and weight loss. Symptoms of aCML may include easy bruising or bleeding and feeling tired or weak. Myelodysplastic/myeloproliferative diseases may progress to acute leukemia. There are different types of treatment for individuals with one of these diseases, which may include chemotherapy , another drug therapy, stem cell transplant and/or supportive care.

MalaCards based summary : Myelodysplastic/myeloproliferative Neoplasm, also known as myelodysplastic/myeloproliferative disease, is related to atypical chronic myeloid leukemia and juvenile myelomonocytic leukemia. An important gene associated with Myelodysplastic/myeloproliferative Neoplasm is NRAS (NRAS Proto-Oncogene, GTPase), and among its related pathways/superpathways are ERK Signaling and Akt Signaling. The drugs Mercaptopurine and Methotrexate have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and bone marrow, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 A myeloid neoplasm that results in the overproduction of white blood cells.

Related Diseases for Myelodysplastic/myeloproliferative Neoplasm

Diseases related to Myelodysplastic/myeloproliferative Neoplasm via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 128)
# Related Disease Score Top Affiliating Genes
1 atypical chronic myeloid leukemia 31.8 U2AF1 TET2 SRSF2 SETBP1 RARS1 LUC7L2
2 juvenile myelomonocytic leukemia 30.9 U2AF1 TET2 SETBP1 PTPN11 NRAS NF1
3 thrombocytosis 30.8 U2AF1 TET2 STAT5B JAK2 CSF2 ASXL1
4 monocytic leukemia 30.5 KMT2A FLT3 CSF2
5 lymphocytic leukemia 30.4 PTPN11 KMT2A CSF2 ABL1
6 hypereosinophilic syndrome 30.4 STAT5B JAK2 CSF2 ABL1
7 polycythemia 30.4 TET2 STAT5B JAK2 ASXL1 ABL1
8 megakaryocytic leukemia 30.2 U2AF1 KMT2A JAK2 CSF2
9 mastocytosis 29.9 TET2 STAT5B SRSF2 JAK2 FLT3 ASXL1
10 essential thrombocythemia 29.7 U2AF1 TET2 STAT5B PTPN11 JAK2 CSF2
11 polycythemia vera 29.6 TET2 STAT5B PTPN11 JAK2 DNMT3A CSF2
12 systemic mastocytosis 29.5 TET2 STAT5B SRSF2 PTPN11 NRAS JAK2
13 aplastic anemia 29.5 U2AF1 TET2 NRAS FLT3 CSF3R CSF2
14 chronic myelomonocytic leukemia 29.3 U2AF1 TET2 SRSF2 SETBP1 PTPN11 NRAS
15 acute promyelocytic leukemia 29.2 STAT5B RARS1 NRAS KMT2A HRAS FLT3
16 myelofibrosis 29.2 U2AF1 TET2 STAT5B SRSF2 SETBP1 JAK2
17 myeloproliferative neoplasm 29.0 U2AF1 TET2 STAT5B PTPN11 NRAS NF1
18 myeloid leukemia 28.9 U2AF1 TET2 STAT5B PTPN11 NRAS KMT2A
19 leukemia 28.8 U2AF1 PTPN11 NRAS NF1 KMT2A JAK2
20 leukemia, acute lymphoblastic 28.6 U2AF1 STAT5B PTPN11 MIR196A1 KMT2A JAK2
21 myelodysplastic syndrome 28.1 U2AF1 TET2 STAT5B SRSF2 SETBP1 PTPN11
22 leukemia, chronic myeloid 27.6 U2AF1 STAT5B SETBP1 PTPN11 NRAS NF1
23 leukemia, acute myeloid 27.3 U2AF1 TET2 STAT5B SRSF2 SETBP1 RARS1
24 unclassified myelodysplastic/myeloproliferative disease 12.6
25 refractory anemia 10.6
26 malignant anus melanoma 10.5 NRAS HRAS
27 acneiform dermatitis 10.5 NRAS HRAS
28 central nervous system melanocytic neoplasm 10.4 NRAS HRAS
29 malignant dermis tumor 10.4 NRAS HRAS
30 cytogenetically normal acute myeloid leukemia 10.4 KMT2A FLT3
31 malignant skin fibrous histiocytoma 10.4 NRAS HRAS
32 amegakaryocytic thrombocytopenia, congenital 10.4 U2AF1 LUC7L2 JAK2
33 testicular spermatocytic seminoma 10.4 PTPN11 HRAS DNMT3A
34 vulvar melanoma 10.4 NRAS NF1 HRAS
35 malignant spindle cell melanoma 10.4 NRAS NF1 HRAS
36 specific learning disability 10.4 PTPN11 NF1
37 pulmonic stenosis 10.4 PTPN11 NF1 HRAS
38 nevus, epidermal 10.4 NRAS NF1 HRAS
39 uveal disease 10.3 U2AF1 NRAS HRAS
40 costello syndrome 10.3 PTPN11 NF1 HRAS
41 neurofibromatosis, type iv, of riccardi 10.3 PTPN11 NF1 HRAS
42 leukemia, acute monocytic 10.3 U2AF1 KMT2A FLT3
43 childhood leukemia 10.3 PTPN11 KMT2A ABL1
44 acute monoblastic leukemia 10.3 NF1 KMT2A CSF2
45 cebpa-associated familial acute myeloid leukemia 10.3 JAK2 FLT3 DNMT3A
46 skin granular cell tumor 10.3 PTPN11 NF1
47 ras-associated autoimmune leukoproliferative disorder 10.3 RARS1 NRAS HRAS
48 neutropenia, severe congenital, 3, autosomal recessive 10.3 CSF3R CSF2
49 systemic mastocytosis with associated hematologic neoplasm 10.3 TET2 SRSF2 ASXL1
50 langerhans cell histiocytosis 10.3 U2AF1 NRAS CSF2

Graphical network of the top 20 diseases related to Myelodysplastic/myeloproliferative Neoplasm:



Diseases related to Myelodysplastic/myeloproliferative Neoplasm

Symptoms & Phenotypes for Myelodysplastic/myeloproliferative Neoplasm

GenomeRNAi Phenotypes related to Myelodysplastic/myeloproliferative Neoplasm according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 9.68 HRAS
2 Decreased viability GR00173-A 9.68 FLT3
3 Decreased viability GR00221-A-1 9.68 ABL1 FLT3 HRAS NF1 NRAS
4 Decreased viability GR00221-A-2 9.68 ABL1 HRAS NF1
5 Decreased viability GR00221-A-3 9.68 ABL1 HRAS NRAS
6 Decreased viability GR00221-A-4 9.68 FLT3 NF1
7 Decreased viability GR00342-S-1 9.68 ABL1
8 Decreased viability GR00342-S-2 9.68 ABL1
9 Decreased viability GR00342-S-3 9.68 ABL1
10 Decreased viability GR00402-S-2 9.68 ABL1 FLT3 HRAS NF1 NRAS

MGI Mouse Phenotypes related to Myelodysplastic/myeloproliferative Neoplasm:

45 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.39 ABL1 ASXL1 CSF2 CSF3R DNMT3A HRAS
2 cellular MP:0005384 10.37 ABL1 ASXL1 CSF2 CSF3R DNMT3A FLT3
3 endocrine/exocrine gland MP:0005379 10.31 ABL1 ASXL1 CSF2 DNMT3A FLT3 HRAS
4 hematopoietic system MP:0005397 10.3 ABL1 ASXL1 CSF2 CSF3R DNMT3A FLT3
5 growth/size/body region MP:0005378 10.29 ABL1 ASXL1 CSF2 DNMT3A FLT3 HRAS
6 cardiovascular system MP:0005385 10.28 ABL1 CSF2 DNMT3A HRAS JAK2 KMT2A
7 homeostasis/metabolism MP:0005376 10.25 ABL1 ASXL1 CSF2 DNMT3A FLT3 HRAS
8 immune system MP:0005387 10.25 ABL1 ASXL1 CSF2 CSF3R DNMT3A FLT3
9 mortality/aging MP:0010768 10.16 ABL1 ASXL1 CSF2 CSF3R DNMT3A FLT3
10 craniofacial MP:0005382 10.11 ABL1 ASXL1 CSF2 HRAS KMT2A NF1
11 integument MP:0010771 10.02 CSF2 HRAS JAK2 KMT2A NF1 NRAS
12 liver/biliary system MP:0005370 9.97 ABL1 ASXL1 JAK2 KMT2A NF1 NRAS
13 neoplasm MP:0002006 9.85 ASXL1 CSF2 FLT3 HRAS JAK2 KMT2A
14 normal MP:0002873 9.61 ABL1 HRAS JAK2 KMT2A NF1 NRAS
15 skeleton MP:0005390 9.36 ABL1 ASXL1 CSF2 DNMT3A FLT3 HRAS

Drugs & Therapeutics for Myelodysplastic/myeloproliferative Neoplasm

Drugs for Myelodysplastic/myeloproliferative Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 307)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mercaptopurine Approved Phase 3 50-44-2 667490
2
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
3
leucovorin Approved Phase 3 58-05-9 6006 143
4
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
5
Daunorubicin Approved Phase 3 20830-81-3 30323
6
Idarubicin Approved Phase 3 58957-92-9 42890
7
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
8
Thioguanine Approved Phase 3 154-42-7 2723601
9
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
10
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
11
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
12
Acyclovir Approved Phase 3 59277-89-3 2022
13
Perphenazine Approved Phase 3 58-39-9 4748
14
Baclofen Approved Phase 3 1134-47-0 2284
15
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
16
Amitriptyline Approved Phase 3 50-48-6 2160
17
Norgestimate Approved, Investigational Phase 3 35189-28-7 6540478
18
Moxifloxacin Approved, Investigational Phase 3 151096-09-2, 354812-41-2 152946
19
Polyestradiol phosphate Approved Phase 3 28014-46-2
20
Estradiol Approved, Investigational, Vet_approved Phase 3 50-28-2 5757
21
Ethinyl Estradiol Approved Phase 3 57-63-6 5991
22
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
23
Tretinoin Approved, Investigational, Nutraceutical Phase 3 302-79-4 5538 444795
24
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
25 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
26 Folic Acid Antagonists Phase 3
27 Dermatologic Agents Phase 3
28 Folate Phase 3
29 Cyclosporins Phase 3
30 Antifungal Agents Phase 3
31 Vitamin B9 Phase 3
32 Vitamin B Complex Phase 3
33 Analgesics, Non-Narcotic Phase 3
34 Analgesics Phase 3
35 Keratolytic Agents Phase 3
36 Antipsychotic Agents Phase 3
37 Central Nervous System Depressants Phase 3
38 Tranquilizing Agents Phase 3
39 Analgesics, Opioid Phase 3
40 Neurotransmitter Agents Phase 3
41 Psychotropic Drugs Phase 3
42 Cola Phase 3
43 Ophthalmic Solutions Phase 3
44 Hydrocortisone hemisuccinate Phase 3
45 Hydrocortisone 17-butyrate 21-propionate Phase 3
46 Hydrocortisone-17-butyrate Phase 3
47
asparaginase Phase 3
48 Narcotics Phase 3
49 Anesthetics Phase 3
50 Adjuvants, Anesthesia Phase 3

Interventional clinical trials:

(show top 50) (show all 249)
# Name Status NCT ID Phase Drugs
1 Intravenous Low-Dose Decitabine Versus Supportive Care in Elderly Patients With Primary Myelodysplastic Syndrome (MDS) (>10% Blasts or High-Risk Cytogenetics), Secondary MDS or Chronic Myelomonocytic Leukemia (CMML) Who Are Not Eligible for Intensive Therapy: An EORTC-German MDS Study Group Randomized Phase III Study Unknown status NCT00043134 Phase 3 decitabine
2 Prospective Study of the Diagnosis and Treatment of Myelodysplastic Syndromes (MDS) in Childhood Unknown status NCT00047268 Phase 3 cytarabine;mercaptopurine
3 A Randomized Double-Blind Controlled Trial of Ketamine Versus Placebo in Conjunction With Best Pain Management in Neuropathic Pain in Cancer Patients Unknown status NCT01316744 Phase 3 ketamine hydrochloride
4 Phase III Trial of T Lymphocyte Depletion by Elutriation and CD34 Add-Back for Allogeneic Bone Marrow Transplantation Completed NCT00265837 Phase 3
5 Allogeneic Blood or Marrow Transplantation for Hematologic Malignancy and Aplastic Anemia Completed NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
6 Randomized Placebo Controlled Double Blind Study of Restasis Versus Placebo in Primary Prevention of Ocular GVHD After Allogeneic Stem Cell Transplantation Completed NCT00755040 Phase 3 cyclosporine ophthalmic emulsion
7 HSCT-CHESS to Enhance Hematopoietic Transplant Recovery Completed NCT00782145 Phase 3
8 Protocol for Patients With High Risk (Resistant, Refractory, Relapsed or Adverse Cytogenetic) AML Completed NCT00005863 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;fludarabine phosphate;tretinoin
9 A Randomized Trial for Patients With Acute Myeloid Leukemia or High Risk Myelodysplatic Syndrome Aged 60 or Over Completed NCT00005823 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;hydroxyurea;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin;valspodar
10 Treatment of Children With Down Syndrome (DS) and Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Transient Myeloproliferative Disorder (TMD): A Phase III Group-Wide Study Completed NCT00003593 Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;methotrexate;therapeutic hydrocortisone;thioguanine
11 A Phase III Multicenter Study of Cytomegalovirus Prophylaxis With Valacyclovir for the Prevention of Serious Fungal and Bacterial Infections Among Cytomegalovirus Seronegative Recipients of Cytomegalovirus Seropositive Sx Stem Cell Transplants Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
12 Preparatory Aid to Improve Decision Making About Cancer Clinical Trials (PRE-ACT) Completed NCT00750009 Phase 3
13 The Use of American Ginseng (Panax Quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind, Placebo-Controlled Phase III Study Completed NCT00719563 Phase 3 American ginseng
14 Phase III Randomized Trial of an Opioid Titration Order Sheet Compared to Standard of Care in Patients With Cancer Related Pain. Completed NCT00666211 Phase 3
15 The Use of Topical Baclofen, Amitriptyline HCI, and Ketamine (BAK) in a PLO Gel vs. Placebo for the Treatment of Chemotherapy Induced Peripheral Neuropathy: A Phase III Randomized Double-Blind Placebo Controlled Study Completed NCT00516503 Phase 3 baclofen/amitriptyline/ketamine gel
16 Music Video and Adolescent/Young Adult Resilience During Transplant Completed NCT00305851 Phase 3
17 INSPIRE: An Internet-based RCT for Long-term Survivors of Hematopoietic Stem Cell Transplantation Completed NCT00799461 Phase 3
18 A Phase III Randomized, Multicenter Trial Comparing G-CSF Mobilized Peripheral Blood Stem Cell With Marrow Transplantation From Human Leukocyte Antigen (HLA) Compatible Unrelated Donors (BMT CTN #0201) Completed NCT00075816 Phase 3
19 A Multi-center Phase III Study Comparing Nonmyeloablative Conditioning With TBI Versus Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies Completed NCT00075478 Phase 3 Fludarabine Phosphate;Mycophenolate Mofetil;Cyclosporine
20 A Multi-center Phase III Study Comparing Myeloablative to Nonmyeloablative Transplant Conditioning in Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia Completed NCT00322101 Phase 3 cyclophosphamide;mycophenolate mofetil;busulfan;cyclosporine;fludarabine phosphate;tacrolimus;methotrexate
21 A Randomized Double Blinded Trial of Topical Caphosol to Prevent Oral Mucositis in Children Undergoing Hematopoietic Stem Cell Transplantation Completed NCT01305200 Phase 3 supersaturated calcium phosphate rinse
22 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
23 Randomized, Double Blinded, Placebo-Controlled Trial of Antibacterial Prophylaxis for the Prevention of Bacterial Infections in the Post-Engraftment Phase After Allogeneic Hematopoeitic Stem Cell Transplantation Terminated NCT00324324 Phase 3 moxifloxacin hydrochloride;Placebo
24 A Randomized Study to Evaluate The Efficacy of Mycophenolate Mofetil Added to The Systemic Immunosuppressive Regimen First Used For Treatment of Chronic Graft-Versus-Host Disease Terminated NCT00089141 Phase 3 mycophenolate mofetil;placebo
25 Phase Two Multicenter Study Of Arsenic Trioxide In Patients With Myelodysplastic Syndromes Unknown status NCT00020969 Phase 2 arsenic trioxide
26 A Multiinstitutional Trial To Evaluate The Prophylactic Use Of NASA-Developed Light Emitting Diodes For The Prevention Of Oral Mucositis In Bone Marrow Transplant Patients Unknown status NCT00036712 Phase 2
27 Transplantation Using Umbilical Cord And Placental Blood Unknown status NCT00008164 Phase 2
28 Phase II Study of Doxercalciferol for the Treatment of Myelodysplastic Syndromes Completed NCT00052832 Phase 2
29 Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) After T-Lymphocyte Depleted Allogeneic BMT for Myelodysplastic Syndromes Completed NCT00003961 Phase 2
30 ALLOGENEIC MARROW OR PERIPHERAL BLOOD STEM CELL TRANSPLANTATION FOR AGNOGENIC MYELOID METAPLASIA WITH MYELOFIBROSIS Completed NCT00002792 Phase 2 busulfan;cyclophosphamide;cyclosporine;methotrexate;tacrolimus
31 Therapy of Early Stage Myelodysplastic Syndrome (MDS) With ATG and Etanercept Completed NCT00217386 Phase 2
32 A Phase II Study of Bexarotene + Sargromastastin as Agents of Differentiation in MDS and AML Completed NCT00425477 Phase 2 bexarotene
33 A Phase I/II Study of Immunologically Engineered rhG-CSF Mobilized Peripheral Blood Stem Cells (PBSC) for Allogeneic Transplant From HLA Identical, Related Donors for Treatment of Myeloid Malignancies Completed NCT00049634 Phase 1, Phase 2 busulfan;cyclophosphamide;cyclosporine;methotrexate
34 Therapy of Advanced Stage Myelodysplastic Syndrome (MDS) With Arsenic Trioxide Given in Combination With Etanercept: A Phase I/II Study Completed NCT00093366 Phase 1, Phase 2 arsenic trioxide
35 Phase II Study of High-Dose Busulfan and Cyclophosphamide Followed by Allogeneic Bone Marrow Transplantation for Patients With Acute Myelogenous Leukemia Completed NCT00004896 Phase 2 busulfan;cyclophosphamide
36 Unrelated Bone Marrow Transplantation With Cyclophosphamide and Total Body Irradiation For Hematologic Malignancies and Bone Marrow Failure States Completed NCT00002809 Phase 2 cyclophosphamide;methotrexate;tacrolimus
37 A Phase II Trial of Combination Therapy With Thalidomide, Arsenic Trioxide, Dexamethasone, and Ascorbic Acid (TADA) in Patients With Chronic Idiopathic Myelofibrosis or Overlap Myelodysplastic/Myeloproliferative Disorders Completed NCT00274820 Phase 2 arsenic trioxide;dexamethasone;thalidomide
38 Conditioning With Targeted Busulfan, Cyclophosphamide and Thymoglobulin for Allogeneic Marrow or Peripheral Blood Stem Cell (PBSC) Transplantation for Myelodysplasia and Myeloproliferative Disorders Completed NCT00054340 Phase 1, Phase 2 busulfan;cyclophosphamide;cyclosporine;methotrexate
39 Hematopoietic Stem Cell Transplantation Using Bone Marrow Or Peripheral Blood Stem Cells From Matched, Unrelated, Volunteer Donors Completed NCT00054327 Phase 2 busulfan;cyclophosphamide;cytarabine;Etoposide
40 Phase II Study of Fludarabine, Carboplatin, and Topotecan With Thalidomide for Patients With Relapsed/Refractory or High Risk Acute Myelogenous Leukemia, Chronic Myeloid Leukemia and Advanced Myelodysplastic Syndromes Completed NCT00053287 Phase 2 carboplatin;fludarabine phosphate;thalidomide;topotecan hydrochloride
41 Low Dose Total-Body Irradiation And Fludarabine Followed By HLA Matched Allogeneic Stem Cell Transplantation For Hematologic Malgnancies - A Multi-Center Study Completed NCT00044954 Phase 2 cyclosporine;fludarabine phosphate;mycophenolate mofetil
42 Autologous Bone Marrow Transplantation for Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome - A Phase II Pilot Study Completed NCT00004899 Phase 2 busulfan;etoposide
43 A Multicenter Study of Unrelated Umbilical Cord Blood as an Alternate Source of Stem Cells for Transplantation Completed NCT00003913 Phase 2 busulfan;cyclophosphamide;methylprednisolone
44 A Pilot Study of Unrelated Umbilical Cord Blood Transplantation in Patients With Severe Aplastic Anemia, Inborn Errors in Metabolism, or Inherited Hematologic Stem Cell Disorders Completed NCT00003336 Phase 2 busulfan;cyclophosphamide;melphalan;methylprednisolone
45 Allogeneic Peripheral Blood Progenitor Cell Transplantation Using Histocompatible Sibling-Matched Donor Cells After High-Dose Busulfan/Cyclophosphamide as Therapy for Hematologic Malignancies Completed NCT00003116 Phase 2 busulfan;cyclophosphamide;cyclosporine
46 Conditioning For Hematopoietic Cell Transplantation With Fludarabine Plus Targeted IV Busulfan and GVHD Prophylaxis With Thymoglobulin, Tacrolimus and Methotrexate in Patients With Myeloid Malignancies Completed NCT00346359 Phase 2 busulfan;fludarabine phosphate;methotrexate;tacrolimus
47 Phase II Study of Intravenous Ganciclovir Followed by Oral Ganciclovir in the Treatment of Reactivation of CMV Following Bone Marrow Transplant Completed NCT00530218 Phase 2 Ganciclovir
48 Orthomolecular Vitamin D3 in Low-Risk Myelodysplastic Syndrome: An Open-Label Clinical Trial Completed NCT00068276 Phase 2
49 The Effect of Cyproheptadine Hydrochloride (Periactin) and Megestrol Acetate (Megace) on Weight in Children With Cancer/Treatment Related Cachexia Completed NCT00066248 Phase 2 cyproheptadine hydrochloride;megestrol acetate
50 Unrelated Umbilical Cord Blood As An Alternate Source Of Stem Cells Transplantation Completed NCT00055653 Phase 2 busulfan;cyclophosphamide;cyclosporine;fludarabine phosphate;melphalan;methylprednisolone

Search NIH Clinical Center for Myelodysplastic/myeloproliferative Neoplasm

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Stem-cell-based therapeutic approaches for Myelodysplastic/myeloproliferative Neoplasm:
NiCord, umbilical cord blood-derived stem/progenitor cells for hemotological diseases
Embryonic/Adult Cultured Cells Related to Myelodysplastic/myeloproliferative Neoplasm:
Umbilical cord blood-derived stem cells (NiCord) PMIDs: 22198152

Cochrane evidence based reviews: myelodysplastic-myeloproliferative diseases

Genetic Tests for Myelodysplastic/myeloproliferative Neoplasm

Anatomical Context for Myelodysplastic/myeloproliferative Neoplasm

MalaCards organs/tissues related to Myelodysplastic/myeloproliferative Neoplasm:

40
Myeloid, Bone, Bone Marrow, T Cells, Liver, Lung, Nk Cells

Publications for Myelodysplastic/myeloproliferative Neoplasm

Articles related to Myelodysplastic/myeloproliferative Neoplasm:

(show top 50) (show all 104)
# Title Authors PMID Year
1
Distinguishing atypical chronic myeloid leukemia from other Philadelphia-negative chronic myeloproliferative neoplasms. 61
31904665 2020
2
Clinicopathologic characteristics, prognostication and treatment outcomes for myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): Mayo Clinic-Moffitt Cancer Center study of 135 consecutive patients. 61
31511613 2020
3
Genetic Factors in Acute Myeloid Leukemia With Myelodysplasia-Related Changes. 61
31977035 2020
4
Myelodysplastic/myeloproliferative neoplasm with eosinophilia as a manifestation of Li Fraumeni Syndrome. 61
31230491 2019
5
Lymphoblastic leukemia following myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms. 61
31017498 2019
6
Despite mutation acquisition in hematopoietic stem cells, JMML-propagating cells are not always restricted to this compartment. 61
31776464 2019
7
Concurrent JAK2 V617F and MPL W515L in myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis. 61
31750750 2019
8
JAK2 exon 12 mutation in myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis: Not an exclusive mutation to polycythaemia vera. 61
31418453 2019
9
"Bone marrow aspirate automated counts on hematology analyzers: formulating a scoring system based on hematology parameters, to discriminate reactive versus myelodysplastic syndrome-related bone marrows". 61
31102331 2019
10
Revisiting diagnostic criteria for myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis: Borderline cases without anemia exist. 61
30811101 2019
11
Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis: "2019 Update on Diagnosis, Risk-stratification, and Management". 61
30618061 2019
12
Chronic Neutrophilic Leukemia: Current and Future Perspectives. 61
30581159 2019
13
NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy. 61
30902805 2019
14
Myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN with RS-T) complicated by hyperleukocytosis and gene analysis in relation to leukocytosis. 61
30726782 2019
15
A Case of SF3B1-Positive Myelodysplastic/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis 61
30468430 2019
16
Gender disparity in the survival of patients with primary myelodysplastic syndrome. 61
30854142 2019
17
[Essential thrombocythemia correctly diagnosed through the guidance of comprehensive genomic profiling]. 61
31902812 2019
18
Molecular Cytogenetic Characterization of a Case of a Myelodysplastic/Myeloproliferative Neoplasm, Chronic Myelomonocytic Leukemia-1 (CMML-1) with Abnormal Karyotype with an Apparent Monosomy 7 Resulting in Rearrangements Involving Chromosomes 7 and 21. 61
30840601 2019
19
[Concurrent CALR and SF3B1 gene mutations in a patient with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis]. 61
31484889 2019
20
Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults: Recommendations From the European Hematology Association and the European LeukemiaNet. 61
31723789 2018
21
Hypomethylating agents (HMAs) effect on myelodysplastic/myeloproliferative neoplasm unclassifiable (MDS/MPN-U): single institution experience. 61
29465270 2018
22
Refractoriness to red blood cell transfusion therapy due to hypersplenism. 61
30260482 2018
23
Mutational landscape of myelodysplastic/myeloproliferative neoplasm-unclassifiable. 61
30242087 2018
24
Integrated molecular profiling of juvenile myelomonocytic leukemia. 61
29437595 2018
25
Sipa1 deficiency-induced bone marrow niche alterations lead to the initiation of myeloproliferative neoplasm. 61
29514790 2018
26
[FGFR1-mutated B-cell acute lymphoblastic leukemia transforming to myelodysplastic / myeloproliferative neoplasm and acute myeloid leukemia]. 61
30078796 2018
27
Evaluation by Flow Cytometry of Mature Monocyte Subpopulations for the Diagnosis and Follow-Up of Chronic Myelomonocytic Leukemia. 61
29707521 2018
28
[Myelodysplastic/myeloproliferative neoplasm: a histopathological review]. 61
30305512 2018
29
Atypical chronic myeloid leukaemia - a rare subtype of myelodysplastic/myeloproliferative neoplasm. 61
29692658 2018
30
Oligomonocytic chronic myelomonocytic leukemia (chronic myelomonocytic leukemia without absolute monocytosis) displays a similar clinicopathologic and mutational profile to classical chronic myelomonocytic leukemia. 61
28548124 2017
31
Atypical chronic myeloid leukemia with isochromosome (X)(p10): A case report. 61
28927137 2017
32
Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified and reactive idiopathic hypereosinophilic syndrome. 61
28495918 2017
33
Generalized palisaded neutrophilic and granulomatous dermatitis-a cutaneous manifestation of chronic myelomonocytic leukemia? A clinical, histopathological, and molecular study of 3 cases. 61
28442268 2017
34
Bone marrow morphology and disease progression in congenital thrombocytopenia: a detailed clinicopathologic and genetic study of eight cases. 61
28059092 2017
35
Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis (RARS-T): 2017 update on diagnosis, risk-stratification, and management. 61
28188970 2017
36
Myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis with co-mutated JAK2 and SF3B1. 61
28153838 2017
37
Acute myeloid leukemia with t(3;21)(q13;q22), a novel simple variant of the 21q22/RUNX1 translocation. 61
28190862 2017
38
Suspected myelodysplastic/myeloproliferative neoplasm in a feline leukemia virus-negative cat. 61
27870069 2016
39
[Juvenile myelomonocytic leukemia: A three-case series]. 61
27789175 2016
40
Genomic profiling and directed ex vivo drug analysis of an unclassifiable myelodysplastic/myeloproliferative neoplasm progressing into acute myeloid leukemia. 61
27240832 2016
41
Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia. 61
27385790 2016
42
Urgent Coronary Artery Bypass Surgery in a Patient with Postinfarction Angina and Active Myelomonocytic Leukaemia. 61
27990115 2016
43
Trim33/Tif1γ is involved in late stages of granulomonopoiesis in mice. 61
27130375 2016
44
Impact of centralized evaluation of bone marrow histology in systemic mastocytosis. 61
26914980 2016
45
Timing of the loss of Pten protein determines disease severity in a mouse model of myeloid malignancy. 61
26764354 2016
46
Anti-proliferative effects of T cells expressing a ligand-based chimeric antigen receptor against CD116 on CD34(+) cells of juvenile myelomonocytic leukemia. 61
26983639 2016
47
Reassessment of H&E stained clot specimens and immunohistochemistry of phosphorylated Stat5 for histological diagnosis of MDS/MPN. 61
26517624 2015
48
Atypical CML with massive splenic infarct: an extremely rare presentation. 61
26564117 2015
49
Flow cytometry immunophenotypic findings in chronic myelomonocytic leukemia and its utility in monitoring treatment response. 61
25354960 2015
50
[Cutaneous extramedullary hematopoiesis associated with myelodysplastic/myeloproliferative neoplasm, unclassifiable]. 61
26256930 2015

Variations for Myelodysplastic/myeloproliferative Neoplasm

Expression for Myelodysplastic/myeloproliferative Neoplasm

Search GEO for disease gene expression data for Myelodysplastic/myeloproliferative Neoplasm.

Pathways for Myelodysplastic/myeloproliferative Neoplasm

Pathways related to Myelodysplastic/myeloproliferative Neoplasm according to GeneCards Suite gene sharing:

(show all 49)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.81 STAT5B NRAS NF1 JAK2 HRAS FLT3
2
Show member pathways
13.39 STAT5B NRAS JAK2 HRAS FLT3 CSF3R
3
Show member pathways
13.24 STAT5B PTPN11 NRAS NF1 JAK2 HRAS
4
Show member pathways
12.78 STAT5B NRAS JAK2 HRAS ABL1
5
Show member pathways
12.72 STAT5B PTPN11 NRAS HRAS FLT3 CSF2
6 12.67 STAT5B NRAS JAK2 HRAS FLT3 CSF3R
7
Show member pathways
12.63 PTPN11 NRAS NF1 HRAS FLT3 ABL1
8
Show member pathways
12.58 PTPN11 NRAS JAK2 HRAS CSF2
9
Show member pathways
12.56 STAT5B PTPN11 NRAS JAK2 HRAS
10
Show member pathways
12.43 STAT5B PTPN11 NRAS JAK2 HRAS
11
Show member pathways
12.38 PTPN11 NF1 JAK2 HRAS
12
Show member pathways
12.37 STAT5B PTPN11 JAK2 HRAS
13
Show member pathways
12.37 PTPN11 NRAS HRAS FLT3
14 12.32 STAT5B NRAS HRAS CSF2
15
Show member pathways
12.27 NRAS NF1 JAK2 HRAS
16
Show member pathways
12.25 STAT5B PTPN11 NRAS NF1 JAK2 HRAS
17
Show member pathways
12.23 STAT5B NRAS JAK2 HRAS FLT3
18 12.22 PTPN11 NRAS HRAS ABL1
19
Show member pathways
12.16 STAT5B PTPN11 JAK2 HRAS
20 12.08 STAT5B PTPN11 JAK2 HRAS
21 12.07 STAT5B PTPN11 JAK2 HRAS ABL1
22
Show member pathways
12.03 NRAS JAK2 HRAS ABL1
23
Show member pathways
12.03 NRAS NF1 JAK2 HRAS
24
Show member pathways
12.02 STAT5B PTPN11 JAK2 HRAS
25
Show member pathways
12.02 STAT5B PTPN11 NRAS JAK2 HRAS
26 11.91 PTPN11 NRAS NF1 HRAS
27 11.88 FLT3 CSF3R CSF2
28
Show member pathways
11.88 STAT5B NRAS JAK2 HRAS
29 11.84 STAT5B NRAS JAK2 HRAS
30
Show member pathways
11.83 STAT5B NRAS HRAS
31
Show member pathways
11.81 STAT5B PTPN11 JAK2 HRAS
32
Show member pathways
11.8 STAT5B PTPN11 JAK2 HRAS CSF3R CSF2
33
Show member pathways
11.79 NRAS HRAS FLT3
34 11.74 STAT5B PTPN11 JAK2
35 11.69 NRAS HRAS FLT3
36
Show member pathways
11.66 NRAS JAK2 HRAS
37
Show member pathways
11.58 STAT5B PTPN11 JAK2 HRAS
38 11.51 NRAS NF1 HRAS
39 11.49 STAT5B PTPN11 JAK2
40 11.46 PTPN11 JAK2 HRAS
41
Show member pathways
11.41 STAT5B PTPN11 JAK2
42 11.39 STAT5B PTPN11 JAK2
43 11.36 STAT5B NRAS HRAS
44 11.36 STAT5B PTPN11 HRAS ABL1
45 11.28 NF1 HRAS CSF2
46
Show member pathways
11.22 PTPN11 JAK2 HRAS
47
Show member pathways
11.19 STAT5B PTPN11 HRAS
48 11.11 STAT5B PTPN11 NRAS JAK2 HRAS CSF3R
49 10.81 NRAS HRAS

GO Terms for Myelodysplastic/myeloproliferative Neoplasm

Cellular components related to Myelodysplastic/myeloproliferative Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.86 U2AF1 TET2 STAT5B SRSF2 SETBP1 RARS1
2 nucleoplasm GO:0005654 9.44 U2AF1 STAT5B SRSF2 SETBP1 RARS1 PTPN11

Biological processes related to Myelodysplastic/myeloproliferative Neoplasm according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 chromatin organization GO:0006325 9.72 TET2 KMT2A JAK2 DNMT3A ASXL1
2 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.69 PTPN11 JAK2 ABL1
3 regulation of cell proliferation GO:0042127 9.67 STAT5B NF1 CSF2 ABL1
4 Ras protein signal transduction GO:0007265 9.63 NRAS NF1 HRAS
5 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.61 JAK2 FLT3 CSF2
6 negative regulation of cell-cell adhesion GO:0022408 9.54 JAK2 ABL1
7 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.52 STAT5B JAK2
8 dendritic cell differentiation GO:0097028 9.49 FLT3 CSF2
9 regulation of myeloid cell differentiation GO:0045637 9.48 CSF3R CSF2
10 positive regulation of mitotic cell cycle GO:0045931 9.43 STAT5B PTPN11 ABL1
11 cytokine-mediated signaling pathway GO:0019221 9.43 STAT5B PTPN11 JAK2 FLT3 CSF3R CSF2
12 Bergmann glial cell differentiation GO:0060020 9.4 PTPN11 ABL1
13 platelet-derived growth factor receptor signaling pathway GO:0048008 9.33 PTPN11 JAK2 ABL1
14 MAPK cascade GO:0000165 9.1 NRAS NF1 JAK2 HRAS FLT3 CSF2

Molecular functions related to Myelodysplastic/myeloproliferative Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.6 U2AF1 TET2 STAT5B SRSF2 SETBP1 RARS1
2 nucleotide binding GO:0000166 9.35 RARS1 NRAS JAK2 HRAS FLT3
3 insulin receptor substrate binding GO:0043560 9.26 PTPN11 JAK2
4 peptide hormone receptor binding GO:0051428 9.16 PTPN11 JAK2

Sources for Myelodysplastic/myeloproliferative Neoplasm

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....